Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-Blind, randomized, placebo-controlled study

Abstract

BackgroundPatients with mixed hyperlipidemia usually are in need of combination therapy to achieve low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) target values for reduction of cardiovascular risk. This study investigated the efficacy and safety of adding a new hypolipidemic agent, coenzyme A (CoA) to stable statin therapy in patients with mixed hyperlipidemia.MethodsIn this multi-center, 8-week, double-blind study, adults who had received ≥8 weeks of stable statin therapy and had hypertriglyceridemia (TG level at 2.3-6.5 mmol/L) were randomized to receive CoA 400 U/d or placebo plus stable dosage of statin. Efficacy was assessed by the changes in the levels and patterns of lipoproteins. Tolerability was assessed by the incidence and severity of adverse events (AEs).ResultsA total of 304 patients with mixed hyperlipidemia were randomized to receive CoA 400 U/d plus statin or placebo plus statin (n = 152, each group). After treatment for 8 weeks, the mean percent change in TG was significantly greater with CoA plus statin compared with placebo plus statin (-25.9% vs -4.9%, respectively; p = 0.0003). CoA plus statin was associated with significant reductions in TC (-9.1% vs -3.1%; p = 0.0033), LDL-C (-9.9% vs 0.1%; p = 0.003), and non- high-density lipoprotein cholesterol (-13.5% vs -5.7%; p = 0.0039). There was no significant difference in the frequency of AEs between groups. No serious AEs were considered treatment related.ConclusionsIn these adult patients with persistent hypertriglyceridemia, CoA plus statin therapy improved TG and other lipoprotein parameters to a greater extent than statin alone and has no obviously adverse effect.Trial registrationCurrent Controlled Trials ClinicalTrials.gov ID NCT01928342.

Awareness, knowledge and practice of dyslipidaemia management among postgraduate primary care trainees in Malaysia: a cross-sectional study

“…Even among those patients who were on lipid lowering agents, the prevalence of those who achieved the desired lipid level was low. A study in China reported that only 23% of patients with dyslipidaemia received treatment and only 17% achieved the desired lipid level of control 7. Another study among Hispanic/Latinos in the USA also reported only 29.5% patients with dyslipidaemia were receiving lipid lowering treatment 8.…”

New Approach to a Practical Quartz Crystal Microbalance Sensor Utilizing an Inkjet Printing System

“…The limit of detection was found to be 50 ng·mL −1 based on a signal-to-noise ratio of three, with a correlation coefficient of 0.957. High sensitivity CRP (hs-CRP) of <1000 ng·mL −1 is well known as a reliable biomarker in obesity, metabolic syndrome, and diabetes, thus it is critical to know the concentration level as a risk factor [ 23 ]. Therefore, good quantification in the range of 50–1000 ng·mL −1 allows for a meaningful result from the viewpoint of sensor devices in clinical diagnoses.…”

Lysophosphatidylcholine activates the Akt pathway to upregulate extracellular matrix protein production in human aortic valve cells

“…It is a hydrolysis product of phosphatidylcholine (PC) in oxLDL(12). In vertebrate plasma, increased levels of LysoPC have been found in atherosclerotic vascular tissue.…”